Search Result

Results for "

latency

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Cytotoxin (1) Apoptosis (5) Autophagy (4) Bacterial (2) CDK (1) Cholecystokinin Receptor (1) Cholinesterase (ChE) (1) COX (1) EBV (2) Epigenetic Reader Domain (2) HDAC (5) HIV (16) HSP (1) Isotope-Labeled Compounds (2) mGluR (1) Neuropeptide Y Receptor (1) NF-κB (1) NO Synthase (1) Orexin Receptor (OX Receptor) (1) PAI-1 (1) Parasite (2) PI3K (1) PKC (1) Proteasome (2) Reactive Oxygen Species (1) Sodium Channel (1) TGF-beta/Smad (2) TGF-β Receptor (2)
By Research Areas:	Cancer (14) Cardiovascular Disease (1) Infection (17) Inflammation/Immunology (6) Neurological Disease (5)

By Targets:

ADC Cytotoxin (1)

Apoptosis (5)

Autophagy (4)

Bacterial (2)

CDK (1)

Cholecystokinin Receptor (1)

Cholinesterase (ChE) (1)

COX (1)

EBV (2)

Epigenetic Reader Domain (2)

HDAC (5)

HIV (16)

HSP (1)

Isotope-Labeled Compounds (2)

mGluR (1)

Neuropeptide Y Receptor (1)

NF-κB (1)

NO Synthase (1)

Orexin Receptor (OX Receptor) (1)

PAI-1 (1)

Parasite (2)

PI3K (1)

PKC (1)

Proteasome (2)

Reactive Oxygen Species (1)

Sodium Channel (1)

TGF-beta/Smad (2)

TGF-β Receptor (2)

By Research Areas:

Cancer (14)

Cardiovascular Disease (1)

Infection (17)

Inflammation/Immunology (6)

Neurological Disease (5)

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-117724

AZ3976	PAI-1	Cardiovascular Disease
AZ3976 is a potent plasminogen activator inhibitor type 1 (PAI-1) inhibitor with an IC₅₀ value of 26 μM in an enzymatic chromogenic assay. AZ3976 is active with an IC₅₀ of 16 μM in a plasma clot lysis assay. AZ3976 does not bind to active PAI-1 but bound reversibly to latent PAI-1. AZ3976 inhibits PAI-1 by enhancing the latency transition of active PAI-1. AZ3976 displays profibrinolytic activities in a human plasma clot lysis assay .

HY-114268

BRD-K98645985 2 Publications Verification	HIV	Infection
BRD-K98645985 is a BAF (mammalian SWI/SNF) transcriptional repression inhibitor with an EC₅₀ of ~2.37 µM. BRD-K98645985 binds ARID1A-specific BAF complexes, prevents nucleosomal positioning, and potently reverses HIV-1 latency, without T cell activation or toxicity .

HY-155599

HIV-1 protease-IN-10	HIV PKC	Infection
HIV-1 protease-IN-10 (Compound 2) has HIV-1 latency reversing activity (IC₅₀: 0.22 μM). HIV-1 protease-IN-10 binds to the PKCδ C1b domain (IC₅₀: 0.69 μM). HIV-1 protease-IN-10 has stability against esterase-mediated hydrolysis .

HY-147552

HIV-1 inhibitor-35	HIV	Infection
HIV-1 inhibitor-35 (compound 74) is a potent HIV-1 inhibitor with EC₅₀s of 80 nM and 70 nM for LTR and CMV in HEK293 cells, respectively. HIV-1 inhibitor-35 has inhibitory activity against liver cancer cell HepG2 with a CC₅₀ of 40 nM. HIV-1 inhibitor-35 can be used as HIV-1 latency reversing agent .

HY-162077

HIV-IN-10

HIV Infection

HIV-IN-10 is a HIV-1 latency reversing agent .

HIV-IN-10	HIV	Infection
HIV-IN-10 is a HIV-1 latency reversing agent .

HY-10896

JNJ-10397049	Orexin Receptor (OX Receptor)	Neurological Disease
JNJ-10397049 is a potent and selective orexin 2 receptor (OX₂R) antagonist, with a pK_i of 8.3. JNJ-10397049 is 600-fold selective for the OX₂R over the OX₁R .

HY-P1920

*CEF19, Epstein-Barr Virus latent* NA-3A (458-466)**	EBV	Inflammation/Immunology
CEF19, Epstein-Barr Virus latent NA-3A (458-466) is a single peptide epitope, YPLHEQHGM, representing residues 458-466 of the type 1 Epstein-Barr Virus (EBV) nuclear antigen 3A protein (B95.8 strain). CEF19, Epstein-Barr Virus latent NA-3A (458-466) can significantly affect cytotoxic T-lymphocyte (CTL) recognition .

HY-130997

17-GMB-APA-GA

ADC Cytotoxin HSP Infection Cancer

17-GMB-APA-GA is an ADC Cytotoxin. 17-GMB-APA-GA is a potent HSP90 inhibitor and used for latent T. gondii infection research .

17-GMB-APA-GA	ADC Cytotoxin HSP	Infection Cancer
17-GMB-APA-GA is an ADC Cytotoxin. 17-GMB-APA-GA is a potent HSP90 inhibitor and used for latent T. gondii infection research .

HY-103232

IEM-1925 bromide	mGluR	Neurological Disease
IEM-1925 bromide is an orally active glutamate receptor antagonist, increases the latent period and decreases the duration of status epilepticus in rats in a lithium-pilocarpine model of epilepsy .

HY-129810

PD 135158 CAM 1028	Cholecystokinin Receptor	Neurological Disease
PD 135158 (CAM 1028) is a selective CCK_B receptor antagonist with an IC₅₀ of 2.8 nM against mouse cortex CCK_B. PD 135158 shows anxiolytic activity .

HY-P5470

LMP2A (426-434)

EBV Others

LMP2A (426-434) is a biological active peptide. (HLA A2.1-restricted epitope from Epstein-Barr Virus latent membrane protein LMP2 (426-434).)
HY-147553

HIV-1 inhibitor-36

HIV Infection

HIV-1 inhibitor-36 (Compound 2) is a potent HIV-1. HIV-1 inhibitor-36 has the potential for further development as novel latency reversing agents .
HY-147554

HIV-1 inhibitor-37

HIV Infection

HIV-1 inhibitor-37 (Compound 83) is a potent HIV-1. HIV-1 inhibitor-37 has the potential for further development as novel latency reversing agents .
HY-147555

HIV-1 inhibitor-38

HIV Infection

HIV-1 inhibitor-38 (Compound 91) is a potent HIV-1. HIV-1 inhibitor-38 has the potential for further development as novel latency reversing agents .

LMP2A (426-434)	EBV	Others
LMP2A (426-434) is a biological active peptide. (HLA A2.1-restricted epitope from Epstein-Barr Virus latent membrane protein LMP2 (426-434).)

HIV-1 inhibitor-36	HIV	Infection
HIV-1 inhibitor-36 (Compound 2) is a potent HIV-1. HIV-1 inhibitor-36 has the potential for further development as novel latency reversing agents .

HIV-1 inhibitor-37	HIV	Infection
HIV-1 inhibitor-37 (Compound 83) is a potent HIV-1. HIV-1 inhibitor-37 has the potential for further development as novel latency reversing agents .

HIV-1 inhibitor-38	HIV	Infection
HIV-1 inhibitor-38 (Compound 91) is a potent HIV-1. HIV-1 inhibitor-38 has the potential for further development as novel latency reversing agents .

HY-155128

LANA-DNA-IN-2	Others	Infection
LANA-DNA-IN-2 (Compound 20) is a latency-associated nuclear antigen (LANA)-DNA interaction inhibitor. LANA-DNA-IN-2 can be used for research of Kaposi’s sarcoma-associated herpesvirus (KSHV) infection .

HY-15815

Bromosporine 3 Publications Verification	Epigenetic Reader Domain Apoptosis CDK HIV	Cancer
Bromosporine is a potent BET inhibitor with an IC₅₀ value of 2.1 μM for PCAF. Bromosporine can arrest cell cycle and induce apoptosis in cancer cells. Bromosporine exhibits excellent antitumor activity in xenograft mice model when combined with 5-FU (HY-90006). Bromosporine can increase CDK9 T-loop phosphorylation in HIV-1 latency models, resulting the protection of reactivate HIV-1 replication from latency. Bromosporine can be used to research colorectal cancer, acute myeloid leukemia (AML) and AIDS .

HY-10224A

Panobinostat lactate LBH589 lactate; NVP-LBH589 lactate	HDAC HIV Autophagy Apoptosis	Infection Cancer
Panobinostat lactate is a potent and orally active non-selective HDAC inhibitor. Panobinostat lactate has antineoplastic activities. Panobinostat lactate effectively disrupts HIV latency. Panobinostat lactate induces cell apoptosis and autophagy. Panobinostat lactate can be used for the study of refractory or relapsed multiple myeloma .

HY-12651

Primaquine diphosphate 2 Publications Verification Primaquine phosphate; Primaquine bisphosphate	Parasite	Infection Cancer
Primaquine diphosphate is a potent antimalaria agent and a potent gametocytocide in falciparum malaria. Primaquine diphosphate prevents relapse in vivax and ovale malaria .

HY-161243

AChE-IN-56

Cholinesterase (ChE) Neurological Disease

AChe-IN-56 is an orally active inhibitor for acetylcholinesterase enzyme (AChE) with neuroprotective efficacy .

AChE-IN-56	Cholinesterase (ChE)	Neurological Disease
AChe-IN-56 is an orally active inhibitor for acetylcholinesterase enzyme (AChE) with neuroprotective efficacy .

HY-12651S

Primaquine-d3 diphosphate	Isotope-Labeled Compounds Parasite	Infection
Primaquine-d₃ (diphosphate) is the deuterium labeled Primaquine diphosphate. Primaquine Diphosphate (Primaquine phosphate), an 8-aminoquinoline, exerts a broad spectrum of activities against various stages of parasitic malaria. Primaquine Diphosphate remains as the only agent that destroys late hepatic stages and latent tissue forms of Plasmodium vivax and Plasmodium ovale[1][2].

HY-119490

UMB-136	Epigenetic Reader Domain HIV	Infection
UMB-136 is a bromodomain inhibitor. UMB-136 is a promising latency-reversing agent (LRA) for HIV-1 eradication. UMB-136 reactivates HIV-1 in multiple cell models. UMB-136 enhances HIV-1 transcription and increases viral production through the release of P-TEFb .

HY-123671

CYM2503	Neuropeptide Y Receptor	Neurological Disease
CYM2503 is a putative GalR2-positive allosteric modulator. CYM2503 increases the latency to first electrographic seizure and decreases the total time in seizure. CYM2503 also attenuates electroshock-induced seizures in mice. Galanin receptors type 1 (GalR1) and/or type 2 (GalR2) represent unique pharmacological targets for the research of seizures and epilepsy .

HY-P3971

H-Leu-Ser-Lys-Leu-OH	TGF-beta/Smad	Inflammation/Immunology
H-Leu-Ser-Lys-Leu-OH (LSYL) is a latency-associated peptide at the amino terminus of LAP, with inhibitory effect on TGF-β1 activation. H-Leu-Ser-Lys-Leu-OH, binding with KRFK (HY-P3970), can block the signal transduction of TGF-β1, and prevent the progression of hepatic damage and fibrosis .

HY-10224

Panobinostat Maximum Cited Publications 51 Publications Verification LBH589; NVP-LBH589	HDAC Autophagy HIV Apoptosis	Cancer
Panobinostat (LBH589; NVP-LBH589) is a potent and orally active non-selective HDAC inhibitor, and has antineoplastic activities . Panobinostat induces HIV-1 virus production even at low concentration range 8-31 nM, stimulates HIV-1 expression in latently infected cells . Panobinostat induces cell apoptosis and autophagy. Panobinostat can be used for the study of refractory or relapsed multiple myeloma .

HY-N0396

Harpagoside 1 Publications Verification	COX NO Synthase	Inflammation/Immunology
Harpagoside can be obtained by Harpagophytum procumbens, which has anti-inflammatory, anti-cancer, protective activity, and efficacy. Harpagoside has an inhibitory effect on COX-1 and COX-2 active, and suppresses NO production. Harpagoside inhibits HepG2 cell lipid polysaccharide, which is a protein that is expressed horizontally and selectively, and has anti-inflammatory and latent pain effects. Harpagoside has the ability to protect the body, and has a degenerative effect on the β-oxidation (Aβ).

HY-13207

ONX-0914 10+ Cited Publications PR-957	Proteasome Bacterial HIV	Infection Inflammation/Immunology
ONX-0914 (PR-957) is a selective inhibitor of low-molecular mass polypeptide-7 (LMP7), the chymotrypsin-like subunit of the immunoproteasome. ONX-0914 blocks cytokine production and attenuates progression of experimental arthritis. ONX-0914 is a noncompetitive irreversible inhibitor of the mycobacterial proteasome (K_i=5.2 μM). ONX-0914 reactivates latent HIV-1 through p-TEFb activation mediated by HSF-1 .

HY-19618

BRD3308
BRD3308 is a highly selective HDAC3 inhibitor with an IC₅₀ of 54 nM. BRD3308 is 23-fold selectivity for HDAC3 over HDAC1 (IC₅₀ of 1.26 μM) or HDAC2 (IC₅₀ of 1.34 μM). BRD3308 suppresses pancreatic β-cell apoptosis induced by inflammatory cytokines or glucolipotoxic stress, and increases functional insulin release. BRD3308 activates HIV-1 transcription and disrupts HIV-1 latency .

HY-P99708

Livmoniplimab ABBV-151; ARGX-115	TGF-beta/Smad	Cancer
Livmoniplimab (ABBV-151; ARGX-115) is a potent, humanized monoclonal antibody against the LRRC32 (GARP)/TGFβ1 complex. Livmoniplimab blocks LRRC32-mediated latent TGFβ1 activation and release. Livmoniplimab has potential in cancer research as a single anticancer agent or in combination with an anti-PD-1 mAb to inhibit locally advanced or metastatic solid tumors (NCT03821935) .

HY-13207A

ONX-0914 TFA 10+ Cited Publications PR-957 TFA	Proteasome Bacterial HIV	Infection Inflammation/Immunology
ONX-0914 (PR-957) TFA is a selective inhibitor of low-molecular mass polypeptide-7 (LMP7), the chymotrypsin-like subunit of the immunoproteasome. ONX-0914 TFA blocks cytokine production and attenuates progression of experimental arthritis. ONX-0914 TFA is a noncompetitive irreversible inhibitor of the mycobacterial proteasome (K_i=5.2 μM). ONX-0914 TFA reactivates latent HIV-1 through p-TEFb activation mediated by HSF-1 .

HY-10224S

Panobinostat-d4 LBH589-d₄; NVP-LBH589-d₄	HDAC Autophagy HIV Apoptosis	Cancer
Panobinostat-d₄ is the deuterium labeled Panobinostat. Panobinostat (LBH589; NVP-LBH589) is a potent and orally active non-selective HDAC inhibitor, and has antineoplastic activities[1][2]. Panobinostat induces HIV-1 virus production even at low concentration range 8-31 nM, stimulates HIV-1 expression in latently infected cells[4]. Panobinostat induces cell apoptosis and autophagy. Panobinostat can be used for the study of refractory or relapsed multiple myeloma[3].

HY-10224S1

Panobinostat-d4 hydrochloride LBH589-d₄ hydrochloride; NVP-LBH589-d₄ hydrochloride	Isotope-Labeled Compounds HDAC Autophagy HIV Apoptosis	Cancer
Panobinostat-d₄ (hydrochloride) is deuterium labeled Panobinostat. Panobinostat (LBH589; NVP-LBH589) is a potent and orally active non-selective HDAC inhibitor, and has antineoplastic activities[1][2]. Panobinostat induces HIV-1 virus production even at low concentration range 8-31 nM, stimulates HIV-1 expression in latently infected cells[4]. Panobinostat induces cell apoptosis and autophagy. Panobinostat can be used for the study of refractory or relapsed multiple myeloma[3].

HY-123295

HDAC3-IN-T247	HDAC	Infection Cancer
HDAC3-IN-T247 is a potent and selective HDAC3 (histone deacetylase 3) inhibitor, with an IC₅₀ of 0.24 µM. HDAC3-IN-T247 induces a selective increase of NF-κB acetylation in HCT116 cells. HDAC3-IN-T247 shows anticancer and antiviral activity. HDAC3-IN-T247 inhibits growth of cancer cells, and activates HIV gene expression in latent HIV-infected cells .

HY-P1441A

Mambalgin 1 TFA	Sodium Channel
Mambalgin 1 TFA is a selective ASIC1a inhibitor (IC₅₀ values are 192 and 72 nM for human ASIC1a and ASIC1a/1b dimer, respectively). Mambalgin 1 TFA binds to closed/inactive channel. Mambalgin 1 TFA is selective for ASIC1a over ASIC2a, ASIC3, TRPV1, P2X2, 5-HT3, Nav1.8, Cav3.2 and Kv1.2 channels. Mambalgin 1 TFA increases latency of withdrawal response in mouse tail-flick and paw-flick tests.

HY-145432

PI3K-IN-28	PI3K	Cancer
PI3K-IN-28 (Compound 6c) is a potent inhibitor of PI3K. PI3K-IN-28 displays the most potent activity with lower toxic effects on MCF-10a. PI3K-IN-28 displays half-maximal inhibitory concentration (IC₅₀, μM) values of 5.8, 2.3, and 7.9. PI3K-IN-28 is the most potent one with a selectivity index (SI) of 39 and is considered as a latent lead for further optimization of anticancer agents .

HY-P0299A

LSKL, Inhibitor of Thrombospondin (TSP-1) (TFA) 5+ Cited Publications	TGF-β Receptor	Cancer
LSKL, Inhibitor of Thrombospondin (TSP-1) TFA is a latency-associated protein (LAP)-TGFβ derived tetrapeptide and a competitive TGF-β1 antagonist. LSKL, Inhibitor of Thrombospondin (TSP-1) TFA inhibits the binding of TSP-1 to LAP and alleviates renal interstitial fibrosis and hepatic fibrosis. LSKL, Inhibitor of Thrombospondin (TSP-1) TFA suppresses subarachnoid fibrosis via inhibition of TSP-1-mediated TGF-β1 activity, prevents the development of chronic hydrocephalus and improves long-term neurocognitive defects following subarachnoid hemorrhage (SAH). LSKL, Inhibitor of Thrombospondin (TSP-1) TFA can readily crosse the blood-brain barrier .

HY-P0299

LSKL, Inhibitor of Thrombospondin (TSP-1) 5+ Cited Publications	TGF-β Receptor	Cancer
LSKL, Inhibitor of Thrombospondin (TSP-1) is a latency-associated protein (LAP)-TGFβ derived tetrapeptide and a competitive TGF-β1 antagonist. LSKL, Inhibitor of Thrombospondin (TSP-1) inhibits the binding of TSP-1 to LAP and alleviates renal interstitial fibrosis and hepatic fibrosis. LSKL, Inhibitor of Thrombospondin (TSP-1) suppresses subarachnoid fibrosis via inhibition of TSP-1-mediated TGF-β1 activity, prevents the development of chronic hydrocephalus and improves long-term neurocognitive defects following subarachnoid hemorrhage (SAH). LSKL, Inhibitor of Thrombospondin (TSP-1) can readily crosse the blood-brain barrier .

HY-A0068

Aurothioglucose 1 Publications Verification Gold thioglucose	NF-κB HIV Reactive Oxygen Species	Infection Inflammation/Immunology Cancer
Aurothioglucose (Gold thioglucose), containing monovalent gold ion, is a potent active-site inhibitor of TrxR1 (thioredoxin reductase 1), with an IC₅₀ of 65 nM. Aurothioglucose inhibits the DNA binding of NF-κB in vitro. Aurothioglucose shows anti-HIV and anti-rheumatic activities .

JAK/STAT Compound Library	419 compounds
The Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway is central to signaling by cytokine receptors, a superfamily of more than 30 transmembrane proteins that recognize specific cytokines, and is critical in blood formation and immune response. Canonical JAK/STAT signaling begins with the association of cytokines and their corresponding transmembrane receptors. Activated JAKs then phosphorylate latent STAT monomers, leading to dimerization, nuclear translocation, and DNA binding. In mammals, there are four JAKs (JAK1, JAK2, JAK3, TYK2) and seven STATs (STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b, STAT6). Since the JAK/STAT pathway plays a major role in many fundamental processes, such as apoptosis and inflammation, dysfunctional proteins in the pathway may lead to a number of diseases. For example, alterations in JAK/STAT signalling can result in cancer and diseases affecting the immune system, such as severe combined immunodeficiency disorder (SCID). MCE provides 419 compounds that can be used in the study of the JAK/STAT signaling pathway and related diseases.

Cat. No.	Product Name	Target	Research Area

HY-P0299A

LSKL, Inhibitor of Thrombospondin (TSP-1) (TFA) 5+ Cited Publications	TGF-β Receptor	Cancer
LSKL, Inhibitor of Thrombospondin (TSP-1) TFA is a latency-associated protein (LAP)-TGFβ derived tetrapeptide and a competitive TGF-β1 antagonist. LSKL, Inhibitor of Thrombospondin (TSP-1) TFA inhibits the binding of TSP-1 to LAP and alleviates renal interstitial fibrosis and hepatic fibrosis. LSKL, Inhibitor of Thrombospondin (TSP-1) TFA suppresses subarachnoid fibrosis via inhibition of TSP-1-mediated TGF-β1 activity, prevents the development of chronic hydrocephalus and improves long-term neurocognitive defects following subarachnoid hemorrhage (SAH). LSKL, Inhibitor of Thrombospondin (TSP-1) TFA can readily crosse the blood-brain barrier .

HY-P1920

*CEF19, Epstein-Barr Virus latent* NA-3A (458-466)**	EBV	Inflammation/Immunology
CEF19, Epstein-Barr Virus latent NA-3A (458-466) is a single peptide epitope, YPLHEQHGM, representing residues 458-466 of the type 1 Epstein-Barr Virus (EBV) nuclear antigen 3A protein (B95.8 strain). CEF19, Epstein-Barr Virus latent NA-3A (458-466) can significantly affect cytotoxic T-lymphocyte (CTL) recognition .

HY-P5470

LMP2A (426-434)

EBV Others

LMP2A (426-434) is a biological active peptide. (HLA A2.1-restricted epitope from Epstein-Barr Virus latent membrane protein LMP2 (426-434).)

LMP2A (426-434)	EBV	Others
LMP2A (426-434) is a biological active peptide. (HLA A2.1-restricted epitope from Epstein-Barr Virus latent membrane protein LMP2 (426-434).)

HY-P3971

H-Leu-Ser-Lys-Leu-OH	TGF-beta/Smad	Inflammation/Immunology
H-Leu-Ser-Lys-Leu-OH (LSYL) is a latency-associated peptide at the amino terminus of LAP, with inhibitory effect on TGF-β1 activation. H-Leu-Ser-Lys-Leu-OH, binding with KRFK (HY-P3970), can block the signal transduction of TGF-β1, and prevent the progression of hepatic damage and fibrosis .

HY-P1441A

Mambalgin 1 TFA	Sodium Channel
Mambalgin 1 TFA is a selective ASIC1a inhibitor (IC₅₀ values are 192 and 72 nM for human ASIC1a and ASIC1a/1b dimer, respectively). Mambalgin 1 TFA binds to closed/inactive channel. Mambalgin 1 TFA is selective for ASIC1a over ASIC2a, ASIC3, TRPV1, P2X2, 5-HT3, Nav1.8, Cav3.2 and Kv1.2 channels. Mambalgin 1 TFA increases latency of withdrawal response in mouse tail-flick and paw-flick tests.

HY-P0299

LSKL, Inhibitor of Thrombospondin (TSP-1) 5+ Cited Publications	TGF-β Receptor	Cancer
LSKL, Inhibitor of Thrombospondin (TSP-1) is a latency-associated protein (LAP)-TGFβ derived tetrapeptide and a competitive TGF-β1 antagonist. LSKL, Inhibitor of Thrombospondin (TSP-1) inhibits the binding of TSP-1 to LAP and alleviates renal interstitial fibrosis and hepatic fibrosis. LSKL, Inhibitor of Thrombospondin (TSP-1) suppresses subarachnoid fibrosis via inhibition of TSP-1-mediated TGF-β1 activity, prevents the development of chronic hydrocephalus and improves long-term neurocognitive defects following subarachnoid hemorrhage (SAH). LSKL, Inhibitor of Thrombospondin (TSP-1) can readily crosse the blood-brain barrier .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0396

Harpagoside 1 Publications Verification	Structural Classification Iridoids Classification of Application Fields Terpenoids Pedaliaceae Plants Inflammation/Immunology Disease Research Fields Harpagophytum procumbens	COX NO Synthase
Harpagoside can be obtained by Harpagophytum procumbens, which has anti-inflammatory, anti-cancer, protective activity, and efficacy. Harpagoside has an inhibitory effect on COX-1 and COX-2 active, and suppresses NO production. Harpagoside inhibits HepG2 cell lipid polysaccharide, which is a protein that is expressed horizontally and selectively, and has anti-inflammatory and latent pain effects. Harpagoside has the ability to protect the body, and has a degenerative effect on the β-oxidation (Aβ).

Species:	Human (6) Rat (1) Mouse (1)
Tag:	His (2) Tag Free (4) Avi (1)
Source:	HEK293 (5) CHO (1) E. coli (1)

Cat. No.	Compare	Product Name	Species	Source

HY-P71056

	TGF beta 1/TGFB1 Protein, Human (HEK293, Avi) Transforming Growth Factor Beta-1; TGF-Beta-1; latency-Associated Peptide; LAP; TGFB1; TGFB	Human	HEK293
	TGF beta 1/TGFB1 Protein is initially identified as a growth factor that induces the growth of rodent fibroblasts. TGF beta 1/TGFB1 Protein inhibits the cell cycle in the G1 phase. TGF beta 1/TGFB1 is an endogenous factor controlling apoptosis in normal and pathological tissues. TGF beta 1/TGFB1 Protein, Human (HEK293, Avi) is a recombinant protein (A279-S390) produced by HEK293 cells with Avi tag.

HY-P70433

	TGF beta 1/TGFB1 LAP Protein, Human (249a.a, HEK293) Transforming Growth Factor Beta-1; TGF-Beta-1; latency-Associated Peptide; LAP; TGFB1; TGFB	Human	HEK293
	The Latency-associated peptide (LAP) of Transforming growth factor beta-1 (TGF-beta-1) proprotein is a crucial precursor, forming a complex with TGF-beta-1. LAP maintains the latent state of TGF-beta-1 during extracellular matrix storage, ensuring controlled activation. Interactions with 'milieu molecules' like LTBP1, LRRC32/GARP, and LRRC33/NRROS intricately regulate TGF-beta-1 activation. LRRC33/NRROS influences activation in macrophages and microglia, while LRRC32/GARP controls activation on activated regulatory T-cells. Interactions with integrins induce conformational changes in LAP, releasing active TGF-beta-1. LAP orchestrates controlled TGF-beta-1 activation in diverse physiological contexts. TGF beta 1/TGFB1 LAP Protein, Human (249a.a, HEK293) is the recombinant human-derived TGF beta 1/TGFB1 LAP protein, expressed by HEK293 , with tag free. and C33S mutation. The total length of TGF beta 1/TGFB1 LAP Protein, Human (249a.a, HEK293) is 249 a.a., with molecular weight of 20-45 kDa.

HY-P70236

	TGF beta 1/TGFB1 Protein, Human (C33S, 361a.a, HEK293, His) rHuLatent TGF Beta-1-C33S, His; Transforming Growth Factor Beta-1; TGF-Beta-1; latency-Associated Peptide; LAP; TGFB1; TGFB	Human	HEK293
	Latent TGF beta 1/TGFB1 Protein is a large extracellular matrix protein and an associated ligand of fibrillinmicrofibrils. TGF beta 1/TGFB1 Protein, Human (361a.a, HEK293, His) is a recombinant Biotinylated protein (L30-S390) produced by HEK293 cells with His tag.

HY-P70543G

	GMP TGF beta 1/TGFB1 Protein, Human (CHO) 1 Publications Verification Transforming Growth Factor Beta-1; TGF-Beta-1; latency-Associated Peptide; LAP; TGFB1; TGFB; TGF-β1; TGF beta1; TGFbeta 1; TGF-beta 1; TGFbeta; TGF-beta-1	Human	CHO
	TGF beta 1/TGFB1 Protein is initially identified as a growth factor that induces the growth of rodent fibroblasts. TGF beta 1/TGFB1 Protein inhibits the cell cycle in the G1 phase. TGF beta 1/TGFB1 is an endogenous factor controlling apoptosis in normal and pathological tissues. GMP TGF beta 1/TGFB1 Protein, Human (HEK293) is a GMP-grade recombinant protein (A279-S390) produced by CHO cells.

HY-P700150AF

	Animal-Free TGF beta 1/TGFB1 Protein, Human (His) Transforming Growth Factor beta-1; TGF-beta-1; latency-Associated Peptide; LAP; TGFB1; TGFB; TGF-β1; TGF beta1; TGFbeta 1; TGF-beta 1; TGFbeta; TGF-beta-1	Human	E. coli
	TGF beta 1/TGFB1 is a polypeptide member of the transforming growth factor beta superfamily of cytokines. TGF beta 1 is a secreted protein that performs many cellular functions, including the control of cell growth, cell proliferation, cell differentiation, apoptosis, and can regulate the expression and activation of other growth factors, including interferon gamma and tumor necrosis factor alpha. Animal-Free TGF beta 1/TGFB1 Protein, Human (His) is the recombinant human-derived animal-FreeTGF beta 1/TGFB1 protein, expressed by E. coli , with C-His labeled tag. The total length of Animal-Free TGF beta 1/TGFB1 Protein, Human (His) is 112 a.a., with molecular weight of ~13.7 kDa.

HY-P70543

	TGF beta 1/TGFB1 Protein, Human (112a.a, HEK293) Maximum Cited Publications 15 Publications Verification Transforming Growth Factor Beta-1; TGF-Beta-1; latency-Associated Peptide; LAP; TGFB1; TGFB; TGF-β1; TGF beta1; TGFbeta 1; TGF-beta 1; TGFbeta; TGF-beta-1	Human	HEK293
	TGF beta 1/TGFB1 Protein is initially identified as a growth factor that induces the growth of rodent fibroblasts. TGF beta 1/TGFB1 Protein inhibits the cell cycle in the G1 phase. TGF beta 1/TGFB1 is an endogenous factor controlling apoptosis in normal and pathological tissues. TGF beta 1/TGFB1 Protein, Human (112a.a, HEK293) is a recombinant protein (A279-S390) produced by HEK293 cells.

HY-P70648

	TGF beta 1/TGFB1 Protein, Mouse/Rat (HEK293) 5+ Cited Publications TGF-beta-1; CED; DPD1; TGFB; TGF-b1; TGFB1; CEDLAP; latency-associated peptide; TGFbeta; TGF-beta 1 protein; transforming growth factor beta-1; TGF-β1; TGF beta1; TGFbeta 1; TGF-beta 1; TGFbeta	Rat;Mouse	HEK293
	TGF beta 1/TGFB1 Protein, Mouse/Rat (HEK293), is a recombinant cytokine produced in HEK293 cells, is implicated as a key regulator of the development and cyclic remodelling characteristic of reproductive tissues.

Cat. No.	Product Name	Chemical Structure

HY-12651S

Primaquine-d3 diphosphate
Primaquine-d₃ (diphosphate) is the deuterium labeled Primaquine diphosphate. Primaquine Diphosphate (Primaquine phosphate), an 8-aminoquinoline, exerts a broad spectrum of activities against various stages of parasitic malaria. Primaquine Diphosphate remains as the only agent that destroys late hepatic stages and latent tissue forms of Plasmodium vivax and Plasmodium ovale[1][2].

HY-10224S

Panobinostat-d4

Panobinostat-d₄ is the deuterium labeled Panobinostat. Panobinostat (LBH589; NVP-LBH589) is a potent and orally active non-selective HDAC inhibitor, and has antineoplastic activities[1][2]. Panobinostat induces HIV-1 virus production even at low concentration range 8-31 nM, stimulates HIV-1 expression in latently infected cells[4]. Panobinostat induces cell apoptosis and autophagy. Panobinostat can be used for the study of refractory or relapsed multiple myeloma[3].

HY-10224S1

Panobinostat-d4 hydrochloride

Panobinostat-d₄ (hydrochloride) is deuterium labeled Panobinostat. Panobinostat (LBH589; NVP-LBH589) is a potent and orally active non-selective HDAC inhibitor, and has antineoplastic activities[1][2]. Panobinostat induces HIV-1 virus production even at low concentration range 8-31 nM, stimulates HIV-1 expression in latently infected cells[4]. Panobinostat induces cell apoptosis and autophagy. Panobinostat can be used for the study of refractory or relapsed multiple myeloma[3].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks